Sheaff Brock Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-101,500	Closed	-$2.73M	–	493
2019 Q1	$2.73M	Buy	101,500 +1,500	+2%	+$35K	0.33%	67
2018 Q4	$1.62M	Buy	100,000 +27,500	+38%	+$534K	0.25%	81
2018 Q3	$1.5M	Buy	72,500 +22,500	+45%	+$354K	0.14%	102
2018 Q2	$764K	Hold	50,000	–	–	0.07%	191
2018 Q1	$1.12M	Hold	50,000	–	–	0.12%	133
2017 Q4	$1.51M	Hold	50,000	–	–	0.2%	104
2017 Q3	$1.88M	Sell	50,000 -1,000	-2%	-$32.5K	0.25%	92
2017 Q2	$1.42M	Buy	51,000 +1,000	+2%	+$29.8K	0.19%	109
2017 Q1	$1.72M	Hold	50,000	–	–	0.22%	95
2016 Q4	$1.44M	Hold	50,000	–	–	0.18%	111
2016 Q3	$1.59M	Hold	50,000	–	–	0.21%	96
2016 Q2	$1.62M	Sell	50,000 -3,000	-6%	-$100K	0.21%	99
2016 Q1	$1.48M	Hold	53,000	–	–	0.18%	114
2015 Q4	$1.89M	Buy	+53,000	New	+$1.87M	0.21%	113

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sheaff Brock Investment Advisors's ACAD Position: Q2 2019 in Review

Sheaff Brock Investment Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 101,500 shares — an estimated $2.73M sold.

Sheaff Brock Investment Advisors first reported a position in ACAD in Q4 2015 and held it in 14 quarters. The position peaked at $2.73M in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

Sheaff Brock Investment Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 101,500 Acadia Pharmaceuticals shares in Q2 2019, an estimated $2.73M.
Sheaff Brock Investment Advisors first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 14 quarters.
Sheaff Brock Investment Advisors's Acadia Pharmaceuticals position peaked at $2.73M in Q1 2019.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Sheaff Brock Investment Advisors's 13F filing for Q2 2019, filed 31 Jul 2019.